US Patent

US8212033 — Use of substituted quinazoline compounds in treating angiogenesis-related diseases

Method of Use · Assigned to Hutchison Medipharma Enterprises Ltd · Expires 2028-05-09 · 2y remaining

Vulnerability score 83/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating angiogenesis-related diseases using quinazoline compounds with specific chemical structures.

USPTO Abstract

Quinazoline derivatives of the following formula: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , X, and Z are defined herein. It also discloses a method of treating an angiogenesis-related disorder with one of these compounds.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3753`	—
`U-3753`	—

Patent Metadata

Patent number: US8212033
Jurisdiction: US
Classification: Method of Use
Expires: 2028-05-09
Drug substance claim: No
Drug product claim: No
Assignee: Hutchison Medipharma Enterprises Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.